Effect of Intravenous Immunoglobulin (IVIg) on Primate Complement-Dependent Cytotoxicity of Genetically Engineered Pig Cells: Relevance to Clinical Xenotransplantation
Posted by Adam Awdish on
Pooled Human Serum Off The Clot from Innovative Research was used in the following study:
Takayuki Yamamoto, Yehua Cui, Diyan Patel, Abhijit Jagdale, Hayato Iwase, David Ayares, David K. C. Cooper & Hidetaka Hara
Scientific Reports
July 16, 2020
Triple-knockout (TKO) pigs are thought to be ideal sources of organs for clinical xenotransplantation because many humans have no preformed antibody to TKO pig cells. Pig kidney or heart graft survival in nonhuman primates (NHPs) now extends to many months, or in some cases years. It is typically believed that preformed and induced antibodies directed toward the donor vascular endothelium are the primary causative factor in the development of antibody-mediated rejection, believed to result from activation of the vascular endothelium and mediated by antibody and/or complement activation.
Intravenous immunoglobulin (IVIg) preparations are known to have immunomodulatory effects on inflammatory and autoimmune diseases, and are commonly used to treat severe infection and/or to prevent/treat rejection of kidney allografts. Currently, it is unknown whether anti-TKO pig antibodies are present in IVIg.
The purpose of this study was to investigate in vitro whether IVIg contains anti-TKO pig antibodies with cytotoxic effect to pig cells. The results suggest that IVIg administration to human recipients of TKO pig grafts would be safe, however, the specific preparation of IVIg would need to be screened before its administration.
Related products available from Innovative Research also include: